He said he also wanted to boost confidence in
developed in China, where the pharmaceutical industry has been riddled with vaccine scandals.
“There is [doubt] that we can really produce a vaccine ourselves within such a short time. That’s why I put myself forward as a mouse in animal model … to say these words: I am confident. I am healthy. I am all right,” Gao said, without saying which vaccine candidate he took.
‘Robust immune responses’ found in Covid-19 vaccine clinical trials point to 2021 release
Developers in China are pursuing four types of technologies – inactivated, virus-vectored, mRNA and recombinant protein – in the race for a vaccine for Covid-19, the disease caused by the coronavirus. Gao and his colleagues in the Chinese Academy of Sciences have developed a potential recombinant protein vaccine that is in phase II of clinical trials.
The CDC chief is not the first Chinese scientist to take a dose of an experimental vaccine.
from the Academy of Military Medical Sciences, whose team developed a Covid-19 vaccine with Tianjin-based firm CanSino Biologics, injected herself with their candidate before doses were given to phase I volunteers.
And Liu Jingzhen, Communist Party secretary of state-owned Sinopharm Group, was one of 180 senior executives to get shots of one of two inactivated vaccines developed by the group’s subsidiaries.
The executives were given the injections before human trials to show they were safe and caused an immune response.
In all, roughly 1,000 employees of the group have taken the experimental vaccines, which are in phase III human trials.
Scientists at Oxford University share promising news on coronavirus vaccine trials
During the seminar, Gao also said that scientists from China and the United State should team up to fight Covid-19.
“If we don’t work together the virus will work together, and probably in future we might have another Covid-20 … We have to keep up dialogue to keep the openness, transparency and cooperation,” he said.
Thirteen companies in China are building facilities to ramp up vaccine production and Sinopharm’s inactivated vaccines are expected to be ready for the market by the end of this year or early next year.
Gao said countries needed to work together to find ways to distribute the vaccines, which China deemed a public good.
“We [have] got to share this public product. We need to find a way ... to share the vaccine in some areas, like low and middle-income countries where they need vaccines but can’t afford [them],” he said.
Purchase the 120+ page China Internet Report 2020 Pro Edition, brought to you by SCMP Research, and enjoy a 30% discount (original price US$400). The report includes deep-dive analysis, trends, and case studies on the 10 most important internet sectors. Now in its 3rd year, this go-to source for understanding China tech also comes with exclusive access to 6+ webinars with C-level executives, including Charles Li, CEO of HKEX, James Peng, CEO/founder of Pony.ai, and senior executives from Alibaba, Huawei, Kuaishou, Pinduoduo, and more. Offer valid until 31 August 2020. To purchase, please .